Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a report released on Friday. They presently have a $36.00 price target on the stock. Wedbush’s target price suggests a potential upside of 38.57% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the company. Chardan Capital upgraded Intellia Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday. BidaskClub upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday. Leerink Swann restated an “outperform” rating on shares of Intellia Therapeutics in a research report on Wednesday, March 14th. TheStreet downgraded Intellia Therapeutics from a “c-” rating to a “d” rating in a research report on Monday, May 7th. Finally, Cann restated a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, May 1st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Intellia Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $34.83.
NASDAQ:NTLA opened at $25.98 on Friday. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -13.82 and a beta of 2.85. Intellia Therapeutics has a 1 year low of $24.72 and a 1 year high of $25.64.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Tuesday, May 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.07. The firm had revenue of $7.47 million for the quarter, compared to the consensus estimate of $6.14 million. Intellia Therapeutics had a negative return on equity of 31.80% and a negative net margin of 278.64%. sell-side analysts forecast that Intellia Therapeutics will post -2 EPS for the current year.
In related news, insider John M. Leonard sold 8,400 shares of the stock in a transaction on Monday, May 14th. The stock was sold at an average price of $24.00, for a total value of $201,600.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jean Francois Formela sold 6,686 shares of the stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $25.04, for a total value of $167,417.44. The disclosure for this sale can be found here. Insiders sold 54,331 shares of company stock worth $1,305,796 in the last quarter. 12.80% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new stake in shares of Intellia Therapeutics in the first quarter worth $252,000. Barclays PLC raised its position in shares of Intellia Therapeutics by 112.8% in the first quarter. Barclays PLC now owns 19,778 shares of the company’s stock worth $416,000 after buying an additional 10,483 shares in the last quarter. UBS Group AG raised its position in shares of Intellia Therapeutics by 131.6% in the first quarter. UBS Group AG now owns 191,616 shares of the company’s stock worth $4,041,000 after buying an additional 108,878 shares in the last quarter. Platinum Investment Management Ltd. purchased a new stake in shares of Intellia Therapeutics in the first quarter worth $1,159,000. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Intellia Therapeutics in the first quarter worth $204,000. Institutional investors own 54.70% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.